Document is current
Any future updates will be listed below
-
Authors
Bhebhe, Lynnette
Moyo, Sikhulile
Gaseitsiwe, Simani
Pretorius-Holme, Molly
Yankinda, Etienne K.
Manyake, Kutlo
Kgathi, Coulson
Mmalane, Mompati
Lebelonyane, Refeletswe
Gaolathe, Tendani
Bachanas, Pamela
Ussery, Faith
Letebele, Mpho
Makhema, Joseph
Wirth, Kathleen E.
Lockman, Shahin
Essex, Max
Novitsky, Vlad
Ragonnet-Cronin, Manon
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1084362, OPP1175094)
DELTAS Africa Initiative (DEL-15-006)
Wellcome Trust (107752/Z/15/Z)
Fogarty International Center (D43TW010543)
National Institute of Health (U41HG006941)
U.S. President’s Emergency Plan for AIDS Relief (U01 GH000447, U2G GH001911, U2G GH000073, U2G GH002027, U2G GH000419)
Foundation for the National Institutes of Health (K24AI131928)
Medical Research Council (MR/R015600/1)
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 17 August 2022
First Online: 28 August 2022
Declarations
:
: The BCPP study was approved by the Human Research Development Committee (HPDME 13/18/1) (the Institutional Review Board based at the Botswana Ministry of Health and Wellness), and the US Centers for Disease Control and Prevention (Protocol 6475). The study is registered at ClinicalTrials.gov (NCT01965470). All participants provided written informed consent and participants aged 16 to 18Â years provided written assent (with parental or guardian written permission). The data collection procedures were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: SM is an editorial Board Member for BMC Infectious Diseases. All other authors report no competing interests.
